Expert Takeaway From WCLC Congress Involving Innovative Bispecific Antibody for NSCLC

Robert L. Ferris, MD, PhD, Lineberger distinguished professor, executive director, UNC Lineberger Comprehensive Cancer Center and chief of Oncology Services UNC Health System Chapel Hill, NC, shares his insights from the recent World Congress on Lung Cancer held in San Diego, CA. With a focus on innovative therapeutic approaches for non-small cell lung cancer (NSCLC), Dr Ferris highlights a clinical trial that showcases a bispecific antibody targeting both PD-L1 and VEGF. This promising development enhances progression-free survival (PFS) for patients and represents a significant advance in protein engineering. As he connects these ideas to concepts that once seemed like science fiction, Ferris offers an optimistic outlook on the future of cancer therapy, emphasizing the potential for new, more effective combinations that can build upon existing standards of care.
For Ferris’ other takeaways from WCLC regarding SCLC, check out part 2: targetedonc.com/